

ForPatients

by Roche

Advanced Solid Tumors Metastatic Solid Tumors

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT03454243 RXDX-106-01

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of RXDX 106.

Hoffmann-La Roche
Sponsor

Early Phase 1
Phase

NCT03454243 RXDX-106-01
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
